Target

MYCN

N-myc proto-oncogene protein

Also: N-MYC

1open trial
3trials in total
69publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Publication
Recent advances and future directions in targeting MYCN: From undruggable to druggable.
4 Nov 2026· Cancer letters· PUBMED
Publication
MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and Is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma.
3 Nov 2026· Molecular cancer research : MCR· PUBMED
Publication
Lorlatinib-Containing Therapy for MYCN-Amplified, ALK-Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report.
29 Oct 2026· Pediatric blood & cancer· PUBMED
Publication
Combined ATR and mitotic inhibition is effective against MYCN-amplified neuroblastoma.
15 Oct 2026· Molecular cancer therapeutics· PUBMED
Publication
IGF2BP1 in 17q-gain cooperates with MYCN to regulate purine biosynthesis and immunotherapy efficacy in neuroblastoma.
9 Oct 2026· Proceedings of the National Academy of Sciences of the United States of America· PUBMED
Publication
A MYCN-GAL-SREBP1 lipogenic axis drives proliferation in silent corticotroph adenomas.
1 Oct 2026· Neuro-oncology· PUBMED
Publication
In Vivo Cascade Cyclic Amplification Strategy for Detecting the Relative Expression of MYCN mRNA in Neuroblastoma.
25 Sept 2026· ACS sensors· PUBMED
Publication
The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors.
15 Sept 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Immune remodeling and myeloid signature in the bone marrow niche of MYCN-driven neuroblastoma.
15 Sept 2026· BJC reports· PUBMED
Publication
Integrated Genomic and Proteomic Analysis Reveals T-B Lymphocyte Signatures in the MYCN Driven "Immune Desert" of Specific Neuroblastoma Subtypes.
1 Sept 2026· CNS neuroscience & therapeutics· PUBMED
Publication
MYCN reprograms postnatal cells toward embryonic-like transcriptional states and drives tumorigenesis.
27 Aug 2026· Biochemical and biophysical research communications· PUBMED
Publication
Comparative Functional Effects of Abemaciclib and Arcyriaflavin A in MYCN-Amplified and Non-Amplified Neuroblastoma Cells: An Exploratory Transcriptomic Study.
17 Aug 2026· International journal of molecular sciences· PUBMED
Publication
The Lipid Switch: Ultra-High Dose Omega Fatty Acids Determine MYCN Neuroblastoma Fate and Implicate Substrate-Level Oxylipin Competition.
14 Aug 2026· ACS pharmacology & translational science· PUBMED
Publication
Machine Learning-Based Classification of Neuroblastoma Risk Groups and MYCN Status.
11 Aug 2026· Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society· PUBMED
Publication
Comparative ASCL1 Interactome Analysis Reveals CDK2-Cyclin A2 as Suppressors of Differentiation in MYCN-Amplified Neuroblastoma.
4 Aug 2026· Molecular cancer research : MCR· PUBMED
Publication
Targeting MYCN Degradation by HLB-0532259 Induces Senescence in Retinoblastoma.
3 Aug 2026· Investigative ophthalmology & visual science· PUBMED
Publication
A five-gene TAM and MYCN signature predicts prognosis and identifies MTHFD2 as a therapeutic target in neuroblastoma.
1 Aug 2026· Discover oncology· PUBMED
Publication
MYCN-driven metabolic remodelling of the tumour microenvironment in neuroblastoma: implications for stromal biology and CAF heterogeneity.
24 Jul 2026· Cancer metastasis reviews· PUBMED
Publication
PhiKan 083 Inhibits MYCN Expression in Liver Cancer Cells Independent of p53 Pathways.
18 Jul 2026· ACS pharmacology & translational science· PUBMED
Publication
Triple-amplified sequential activation allosteric DNA biosensor for in vivo quantitative detection of MYCN copy number in neuroblastoma.
16 Jul 2026· RSC advances· PUBMED
Publication
5-hydroxymethylcytosine deposition mediates Polycomb repressive complex 2 function in MYCN-amplified neuroblastoma.
16 Jul 2026· iScience· PUBMED
Publication
DMAMCL induces ferroptosis in neuroblastoma by targeting HMOX1 in MYCN-amplified subtypes whereas targeting STEAP3 in MYCN-nonamplified subtypes.
13 Jul 2026· Redox report : communications in free radical research· PUBMED
Publication
LMNTD2-AS1 promotes esophageal squamous cell carcinoma progression by sponging miR-449b-5p to upregulate MYCN.
6 Jul 2026· World journal of surgical oncology· PUBMED
Publication
18F-FDG PET/MRI Multiparametric Imaging Features for Predicting MYCN Amplification Status in Children With High-Risk Neuroblastoma.
26 Jun 2026· Revista de neurologia· PUBMED
Publication
Targeting the MYCN interaction network in neuroblastoma.
17 Jun 2026· Bioscience reports· PUBMED
Publication
MYCN and helicases DDX17 and DDX5 have opposite effects on the production of readthrough-associated chimeric transcripts.
28 May 2026· Cellular and molecular life sciences : CMLS· PUBMED
Publication
Multi‑omics identification of MSI2 as a super-enhancer‑driven vulnerability in MYCN‑amplified neuroblastoma.
16 May 2026· Journal of translational medicine· PUBMED
Publication
MYCN Amplification Drives Ferroptosis Susceptibility via Cysteine Metabolism in Retinoblastoma.
1 May 2026· Investigative ophthalmology & visual science· PUBMED
Publication
KDM4B/DHX9 promotes chemoresistance in small-cell lung cancer through the MYCN-driven signaling pathway.
29 Apr 2026· Oncogene· PUBMED
Publication
ZRANB1 depletion inhibits neuroblastoma progression by destabilizing MYCN through EZH2-mediated deubiquitination.
8 Apr 2026· Cell biology and toxicology· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error